Previous Close | 2.4300 |
Open | 2.4910 |
Bid | 2.5400 x 1300 |
Ask | 2.7500 x 1400 |
Day's Range | 2.4000 - 2.5900 |
52 Week Range | 2.0000 - 13.2000 |
Volume | |
Avg. Volume | 172,700 |
Market Cap | 3.309M |
Beta (5Y Monthly) | 0.56 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -29.8500 |
Earnings Date | Mar 19, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 93.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for CYCC
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a conference call at 4:30pm ET on the same day. Conference call information: Participant Toll-Free Number: 800-579-2543 Primary Participant Dire
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphomaBERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that preclinical proof-of-concept data with the Company’s fadraciclib will be presented at the upcoming American Associatio
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is based on R&D costs incurred in the year ended December 31, 2023. The